Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder

Jaswinder K. Ghuman, Michael G. Aman, Harinder S. Ghuman, Thomas Reichenbacher, Alan Gelenberg, Ron Wright, Sydney A Rice, Carolyn Fort

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: The aim of this study was to report preliminary data regarding effectiveness and tolerability of atomoxetine in 3- to 5-year-old preschool children with attention-deficit/hyperactivity disorder (ADHD). Methods: Nine boys and 3 girls (mean age=5.0±0.72 years) diagnosed with ADHD were treated with atomoxetine in an open-label pilot study. Atomoxetine was gradually titrated to a maximum dose of 1.8mg/kg per day. Results: There was a significant effect of time from baseline to end point on the parent-rated hyperactivity/impulsivity Swanson Nolan and Pelham (SNAP-IV-HI) subscale ratings (F[9, 11]=6.32, p<0.0001). The mean difference between the baseline and end-point parent SNAP-IV-HI scores was 10.2±7.3 (p=0.0005). The rate of positive response (defined as at least a 30% reduction in the end-point parent SNAP-IV-HI scores and a Clinical Global Impressions-Improvement [CGI-I] rating of Much Improved or Very Much Improved) was 75%. The Children's Global Assessment Scale scores improved significantly over time [F(9, 11)=6.24 p<0.001]. The mean end-point daily dose of atomoxetine was 1.59±0.3mg/kg. A high proportion (66.7%) of the preschoolers experienced side effects with atomoxetine. Side effects of defiance, tantrums, aggression, and irritability were most disconcerting to parents, and gastrointestinal complaints were the most commonly reported adverse effects. One child was terminated from the study due to "chest ache." There were no changes in weight, height, or cardiovascular measures. Conclusion: This open-label pilot study provides preliminary evidence of effectiveness and tolerability of atomoxetine for treating ADHD in preschool children, although double-blind, randomized, placebo-controlled studies are needed to confirm this.

Original languageEnglish (US)
Pages (from-to)155-166
Number of pages12
JournalJournal of Child and Adolescent Psychopharmacology
Volume19
Issue number2
DOIs
StatePublished - Apr 1 2009

Fingerprint

Preschool Children
Attention Deficit Disorder with Hyperactivity
Therapeutics
Impulsive Behavior
Aggression
Atomoxetine Hydrochloride
Thorax
Parents
Placebos
Weights and Measures
Pain

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. / Ghuman, Jaswinder K.; Aman, Michael G.; Ghuman, Harinder S.; Reichenbacher, Thomas; Gelenberg, Alan; Wright, Ron; Rice, Sydney A; Fort, Carolyn.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 19, No. 2, 01.04.2009, p. 155-166.

Research output: Contribution to journalArticle

Ghuman, Jaswinder K. ; Aman, Michael G. ; Ghuman, Harinder S. ; Reichenbacher, Thomas ; Gelenberg, Alan ; Wright, Ron ; Rice, Sydney A ; Fort, Carolyn. / Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. In: Journal of Child and Adolescent Psychopharmacology. 2009 ; Vol. 19, No. 2. pp. 155-166.
@article{88b61475d375498fbdf26719e0b7411d,
title = "Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder",
abstract = "Objective: The aim of this study was to report preliminary data regarding effectiveness and tolerability of atomoxetine in 3- to 5-year-old preschool children with attention-deficit/hyperactivity disorder (ADHD). Methods: Nine boys and 3 girls (mean age=5.0±0.72 years) diagnosed with ADHD were treated with atomoxetine in an open-label pilot study. Atomoxetine was gradually titrated to a maximum dose of 1.8mg/kg per day. Results: There was a significant effect of time from baseline to end point on the parent-rated hyperactivity/impulsivity Swanson Nolan and Pelham (SNAP-IV-HI) subscale ratings (F[9, 11]=6.32, p<0.0001). The mean difference between the baseline and end-point parent SNAP-IV-HI scores was 10.2±7.3 (p=0.0005). The rate of positive response (defined as at least a 30{\%} reduction in the end-point parent SNAP-IV-HI scores and a Clinical Global Impressions-Improvement [CGI-I] rating of Much Improved or Very Much Improved) was 75{\%}. The Children's Global Assessment Scale scores improved significantly over time [F(9, 11)=6.24 p<0.001]. The mean end-point daily dose of atomoxetine was 1.59±0.3mg/kg. A high proportion (66.7{\%}) of the preschoolers experienced side effects with atomoxetine. Side effects of defiance, tantrums, aggression, and irritability were most disconcerting to parents, and gastrointestinal complaints were the most commonly reported adverse effects. One child was terminated from the study due to {"}chest ache.{"} There were no changes in weight, height, or cardiovascular measures. Conclusion: This open-label pilot study provides preliminary evidence of effectiveness and tolerability of atomoxetine for treating ADHD in preschool children, although double-blind, randomized, placebo-controlled studies are needed to confirm this.",
author = "Ghuman, {Jaswinder K.} and Aman, {Michael G.} and Ghuman, {Harinder S.} and Thomas Reichenbacher and Alan Gelenberg and Ron Wright and Rice, {Sydney A} and Carolyn Fort",
year = "2009",
month = "4",
day = "1",
doi = "10.1089/cap.2008.054",
language = "English (US)",
volume = "19",
pages = "155--166",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder

AU - Ghuman, Jaswinder K.

AU - Aman, Michael G.

AU - Ghuman, Harinder S.

AU - Reichenbacher, Thomas

AU - Gelenberg, Alan

AU - Wright, Ron

AU - Rice, Sydney A

AU - Fort, Carolyn

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Objective: The aim of this study was to report preliminary data regarding effectiveness and tolerability of atomoxetine in 3- to 5-year-old preschool children with attention-deficit/hyperactivity disorder (ADHD). Methods: Nine boys and 3 girls (mean age=5.0±0.72 years) diagnosed with ADHD were treated with atomoxetine in an open-label pilot study. Atomoxetine was gradually titrated to a maximum dose of 1.8mg/kg per day. Results: There was a significant effect of time from baseline to end point on the parent-rated hyperactivity/impulsivity Swanson Nolan and Pelham (SNAP-IV-HI) subscale ratings (F[9, 11]=6.32, p<0.0001). The mean difference between the baseline and end-point parent SNAP-IV-HI scores was 10.2±7.3 (p=0.0005). The rate of positive response (defined as at least a 30% reduction in the end-point parent SNAP-IV-HI scores and a Clinical Global Impressions-Improvement [CGI-I] rating of Much Improved or Very Much Improved) was 75%. The Children's Global Assessment Scale scores improved significantly over time [F(9, 11)=6.24 p<0.001]. The mean end-point daily dose of atomoxetine was 1.59±0.3mg/kg. A high proportion (66.7%) of the preschoolers experienced side effects with atomoxetine. Side effects of defiance, tantrums, aggression, and irritability were most disconcerting to parents, and gastrointestinal complaints were the most commonly reported adverse effects. One child was terminated from the study due to "chest ache." There were no changes in weight, height, or cardiovascular measures. Conclusion: This open-label pilot study provides preliminary evidence of effectiveness and tolerability of atomoxetine for treating ADHD in preschool children, although double-blind, randomized, placebo-controlled studies are needed to confirm this.

AB - Objective: The aim of this study was to report preliminary data regarding effectiveness and tolerability of atomoxetine in 3- to 5-year-old preschool children with attention-deficit/hyperactivity disorder (ADHD). Methods: Nine boys and 3 girls (mean age=5.0±0.72 years) diagnosed with ADHD were treated with atomoxetine in an open-label pilot study. Atomoxetine was gradually titrated to a maximum dose of 1.8mg/kg per day. Results: There was a significant effect of time from baseline to end point on the parent-rated hyperactivity/impulsivity Swanson Nolan and Pelham (SNAP-IV-HI) subscale ratings (F[9, 11]=6.32, p<0.0001). The mean difference between the baseline and end-point parent SNAP-IV-HI scores was 10.2±7.3 (p=0.0005). The rate of positive response (defined as at least a 30% reduction in the end-point parent SNAP-IV-HI scores and a Clinical Global Impressions-Improvement [CGI-I] rating of Much Improved or Very Much Improved) was 75%. The Children's Global Assessment Scale scores improved significantly over time [F(9, 11)=6.24 p<0.001]. The mean end-point daily dose of atomoxetine was 1.59±0.3mg/kg. A high proportion (66.7%) of the preschoolers experienced side effects with atomoxetine. Side effects of defiance, tantrums, aggression, and irritability were most disconcerting to parents, and gastrointestinal complaints were the most commonly reported adverse effects. One child was terminated from the study due to "chest ache." There were no changes in weight, height, or cardiovascular measures. Conclusion: This open-label pilot study provides preliminary evidence of effectiveness and tolerability of atomoxetine for treating ADHD in preschool children, although double-blind, randomized, placebo-controlled studies are needed to confirm this.

UR - http://www.scopus.com/inward/record.url?scp=65249142203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249142203&partnerID=8YFLogxK

U2 - 10.1089/cap.2008.054

DO - 10.1089/cap.2008.054

M3 - Article

C2 - 19364293

AN - SCOPUS:65249142203

VL - 19

SP - 155

EP - 166

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 2

ER -